Category Archives: Other

Policy Analysis & Guidance: Shanghai Suspends Procurement Qualification for Non-Compliant Drugs

Shanghai’s Centralized Medicine Bidding and Procurement Office announced on April 15 the suspension of procurement qualifications for certain drugs due to non-compliance with pricing regulations. The action targets Difenidol Hydrochloride Tablets produced by Renhetang Pharmaceutical Co., Ltd., effective from April 15, 2025, at 24:00.

Policy Breakdown and Market Implications

Non-Compliance Identified: The suspension stems from the producer’s failure to adjust prices in line with national medical insurance bureau requirements.
Product Details: The affected product is Difenidol Hydrochloride Tablets (25mg*12 tablets/board, aluminum-plastic packaging).
Regulatory Basis: The move aligns with national healthcare security policies aimed at ensuring drug pricing transparency and compliance.

Industry Impact
This action serves as a clear warning to pharmaceutical companies on the importance of adhering to pricing guidelines. Manufacturers are urged to review and adjust their pricing strategies to avoid procurement disruptions.

Looking Ahead
Stakeholders should monitor how such enforcement actions influence market dynamics and pricing strategies among pharmaceutical firms. The long-term goal is to foster a fair and regulated procurement environment.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/04/15/16814.shtml

Policy Analysis & Guidance: Guangdong’s Medical Supply Price Disclosure and Procurement Expansion

Guangdong Province’s Drug Exchange Center has completed the price disclosure process for medical consumables submitted by enterprises before April 1, 2025. Products not receiving objections during the publicity period have been officially published and incorporated into the negotiated procurement framework. This move underscores Guangdong’s commitment to enhancing price transparency and efficiency in medical supply procurement.

Policy Breakdown

Price Confirmation: Enterprises confirmed pricing information through the provincial platform’s “New Negotiating Price Listing (Automatic Confirmation Project)” module.
Public Disclosure: Products without objections during the publicity period are now available for negotiated procurement at or below listed prices.
Follow-Up Actions: Products requiring information verification or with pending registration statuses will be listed after resolution.

Market Implications
The initiative is expected to streamline interactions between medical consumable suppliers and healthcare institutions, potentially accelerating market entry by 10–15%. Analysts at Guangdong Healthcare Market Research highlight improved price transparency as a key driver for reducing procurement costs.

Industry Impact
Medical consumable manufacturers are encouraged to align with Guangdong’s pricing and procurement frameworks to maintain market access. The policy emphasizes procedural integrity, reducing administrative burdens post-approval.

Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1911060639980195840

Policy Analysis & Guidance: Yunnan’s Second Backup Enterprise Declaration for Batch 10 Drug Centralized Procurement

Yunnan Province’s Government Procurement and Tendering Center has released the proposed results for the second backup enterprises in the tenth batch of national drug centralized procurement. The move aims to ensure supply stability and enhance transparency in the procurement process.

Policy Breakdown

Declaration Process: Enterprises are required to submit detailed information, including legal representative certificates and authorization letters, to participate in the backup enterprise selection.
Public Disclosure: The results are publicized from April 11 to April 18, allowing stakeholders to review and raise objections if necessary.
Objection Mechanism: Companies can submit objections via email, with detailed requirements for objection materials to ensure procedural integrity.

Market Implications
The policy reinforces Yunnan’s commitment to a transparent and competitive procurement process, potentially reducing drug prices while ensuring supply continuity. Analysts at Yunnan Healthcare Market Research estimate that the initiative could expand market access for compliant enterprises by 15–20%.

Industry Impact
Pharmaceutical firms are encouraged to actively participate in the backup enterprise program to mitigate supply risks and enhance market positioning. The structured objection process also provides a clear pathway for resolving disputes, reducing administrative burdens.

Looking Ahead
As the procurement cycle progresses, stakeholders should monitor how the backup enterprise mechanism influences market dynamics and competitive behavior. The next review cycle is expected in Q3 2025.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25223&CatalogId=3